<DOC>
	<DOCNO>NCT00840463</DOCNO>
	<brief_summary>This randomize study ambrisentan last 16 week . The study include patient diastolic heart failure pulmonary hypertension . Patients randomize ( 1:1 ) ambrisentan placebo . The ambrisentan matching placebo start 2.5 mg mouth daily increase 5mg 10mg daily , tolerate . Patients see least monthly 16 week . Adverse reaction review require monthly laboratory test ( liver function test pregnancy testing , applicable ) , perform . Patients also complete exercise test ( six minute walk distance ) quality life survey baseline , week 4 week 16 visit . An echocardiogram right heart catheterization leave ventricular end diastolic pressure measurement perform 16 week visit . The primary end-point safety , secondary end-points include catheterization result , echocardiogram result , walk distance quality life survey . The expected completion study 18 month initiation . Ambrisentan FDA approve drug PAH , CHF .</brief_summary>
	<brief_title>Safety Efficacy Trial Treat Diastolic Heart Failure Using Ambrisentan</brief_title>
	<detailed_description>Hypothesis : patient pulmonary hypertension secondary diastolic congestive heart failure ( CHF ) treat ambrisentan 16 week improve hemodynamics , increase exercise capacity improve functional class acceptable safety profile , compare placebo treat patient . Objectives : evaluate safety efficacy ambrisentan treatment patient pulmonary hypertension due diastolic CHF . Efficacy assess improvement hemodynamics ( PVR ( Pulmonary Vascular Resistance ) : primary efficacy endpoint ) , six minute walk distance ( 6MWD ) , World Health Organization ( WHO ) functional class quality life 16 week treatment ambrisentan . Safety ambrisentan compare placebo . Concomitant Medication : Treatment standard medication CHF include diuretic optimal blood pressure control antihypertensive medication allow throughout study period . Diuretics adjustment also allow encourage base plan diuretic management protocol . Approved medication CHF general allow well , though noted medication show benefit diastolic CHF . Patients may endothelin antagonist sildenafil .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<criteria>1 . Catheterization 1 . Elevated pulmonary arterial pressure ( PA mean &gt; 25mmHg ) 2 . Elevated pulmonary vascular resistance ( &gt; 240 dynes.cm.sec5 ) transpulmonary gradient ( &gt; 12 mmHg ) 3 . Elevated LVEDP ( &gt; 15mmHg , â‰¤23 mmHg ) 2 . Evidence leave ventricular diastolic dysfunction : LA &gt; 4.0 , LVH diastolic dysfunction mitral filling pattern 3 . Echocardiogram : Normal mildly reduce LV ejection fraction ( great equal 40 % ) 4 . Symptomatic chronic HF ( WHO functional class IIIV ) 5 . Baseline walk distance 100 400 meter 6 . Age 18 80 ( increase 70 ) Maximal treatment diastolic dysfunction note treating physician change medical therapy one month prior entry 1 . Use endothelin receptor antagonist , prostacyclin PDE5 inhibitor within 4 week enrollment 2 . Exercise capacity limit illness ( lung disease , arthritis , mobility limitation ) 3 . Uncontrolled systemic hypertension 4 . Uncontrolled atrial fibrillation 5 . Severe valvular disease 6 . Pregnant female female child bear potential need use contraceptive agent barrier give teratogenicity associate ERA 's 7 . Uncontrolled OSA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>Diastolic Heart Failure</keyword>
</DOC>